{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:02:53Z","timestamp":1791820973597,"version":"4.3.4"},"reference-count":80,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone produced mainly in osteocytes. In chronic kidney disease (CKD) FGF23 levels increase due to higher production, but also as the result of impaired cleavage and reduced excretion from the body. FGF23 has a significant role in disturbed bone and mineral metabolism in CKD, which leads to a higher cardiovascular risk and mortality in these patients. Current research has emphasized the expression of FGF23 in cardiac myocytes, fibroblasts, and endothelial cells, and in addition to the effects on the kidney, its primary role is in cardiac remodeling in CKD patients. Recent discoveries found a significant link between increased FGF23 levels and anemia development in CKD. This review describes the FGF23 role in cardiac hypertrophy and anemia in the setting of CKD and discusses the best therapeutical approach for lowering FGF23 levels.<\/jats:p>","DOI":"10.3390\/cells12040609","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T02:41:56Z","timestamp":1676342516000},"page":"609","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["FGF23 in Chronic Kidney Disease: Bridging the Heart and Anemia"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-0312","authenticated-orcid":false,"given":"Andreja","family":"Figurek","sequence":"first","affiliation":[{"name":"Institute of Anatomy, University of Zurich, 8057 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1048-2579","authenticated-orcid":false,"given":"Merita","family":"Rroji","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Medicine Tirana, 1001 Tirana, Albania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goce","family":"Spasovski","sequence":"additional","affiliation":[{"name":"University Clinic for Nephrology, Medical Faculty, University St. Cyril and Methodius, 1000 Skopje, North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","article-title":"Regulation of Fibroblast Growth Factor-23 Signaling by Klotho","volume":"281","author":"Kurosu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1128\/MCB.02249-06","article-title":"Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members","volume":"27","author":"Goetz","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1073\/pnas.0902006107","article-title":"Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation","volume":"107","author":"Goetz","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fendo.2018.00189","article-title":"FGF23 Actions on Target Tissues\u2014With and Without Klotho","volume":"9","author":"Richter","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_5","first-page":"9481475","article-title":"Correlation between Soluble \u03b1-Klotho and Renal Function in Patients with Chronic Kidney Disease: A Review and Meta-Analysis","volume":"2018","author":"Wang","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"153865","DOI":"10.1016\/j.metabol.2019.01.006","article-title":"Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting","volume":"103","author":"Bacchetta","year":"2020","journal-title":"Metabolism"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1152\/ajprenal.00606.2015","article-title":"FGF23 from Bench to Bedside Perspective","volume":"310","author":"Kovesdy","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"(2014). Introduction to Volume Two: Atlas of End-Stage Renal Disease in the United States. Am. J. Kidney Dis., 63, e151\u2013e168.","DOI":"10.1053\/j.ajkd.2013.10.025"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fmed.2018.00206","article-title":"Uremic Cardiomyopathy: A New Piece in the Chronic Kidney Disease-Mineral and Bone Disorder Puzzle","volume":"5","author":"Suassuna","year":"2018","journal-title":"Front. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1525-139X.2008.00457.x","article-title":"NON-CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Cardiac Problems in the Dialysis Patient: Beyond Coronary Disease","volume":"21","author":"Remppis","year":"2008","journal-title":"Semin. Dial."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000435838","article-title":"Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment","volume":"5","author":"Gorini","year":"2015","journal-title":"Cardiorenal Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41581-018-0101-8","article-title":"Evolving concepts in the pathogenesis of uraemic cardiomyopathy","volume":"15","author":"Wang","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gfq539","article-title":"Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients","volume":"26","author":"Kirkpantur","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"18320","DOI":"10.1016\/S0021-9258(17)32309-8","article-title":"Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1","volume":"269","author":"Vainikka","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/01.RES.0000109415.17511.18","article-title":"Calcineurin\/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy","volume":"94","author":"Wilkins","year":"2004","journal-title":"Circ. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tanaka, S., Fujita, S.-I., Kizawa, S., Morita, H., and Ishizaka, N. (2016). Association between FGF23, \u03b1-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156860"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/s41598-017-02068-6","article-title":"FGF23\/FGFR4-mediated left ventricular hypertrophy is reversible","volume":"7","author":"Grabner","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/ndt\/gfw454","article-title":"Vitamin D treatment attenuates cardiac FGF23\/FGFR4 signaling and hypertrophy in uremic rats","volume":"32","author":"Grabner","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_21","first-page":"E863","article-title":"FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy","volume":"304","author":"Touchberry","year":"2013","journal-title":"Am. J. Physiol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Figurek, A., Rroji, M., and Spasovski, G. (2021). The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu. Cells, 10.","DOI":"10.3390\/cells10051266"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"791479","DOI":"10.3389\/fcell.2021.791479","article-title":"Comprehensive Expression Analysis of Cardiac Fibroblast Growth Factor 23 in Health and Pressure-induced Cardiac Hypertrophy","volume":"9","author":"Eitner","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fendo.2018.00278","article-title":"Paracrine Effects of FGF23 on the Heart","volume":"9","author":"Haffner","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/ndt\/gfy006","article-title":"Fibroblast growth factor 23 is induced by an activated renin\u2013angiotensin\u2013aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts","volume":"33","author":"Kirchhoff","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41598-017-02709-w","article-title":"FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts","volume":"7","author":"Smith","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biocel.2017.09.009","article-title":"FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-\u03b2 autoinduction","volume":"92","author":"Smith","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"64649","DOI":"10.18632\/oncotarget.11623","article-title":"FGF23 promotes myocardial fibrosis in mice through activation of \u03b2-catenin","volume":"7","author":"Hao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/jbmr.2527","article-title":"Experimental Myocardial Infarction Upregulates Circulating Fibroblast Growth Factor-23","volume":"30","author":"Andrukhova","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/BOR.0b013e32834b3309","article-title":"\u03b2-catenin signaling","volume":"23","author":"Lam","year":"2011","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fmed.2015.00059","article-title":"Signaling in Fibrosis: TGF-\u03b2, WNT, and YAP\/TAZ Converge","volume":"2","author":"Piersma","year":"2015","journal-title":"Front. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.kint.2019.05.018","article-title":"FGF23 and inflammation\u2014a vicious coalition in CKD","volume":"96","author":"Czaya","year":"2019","journal-title":"Kidney Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3389\/fendo.2018.00320","article-title":"Role of Fibroblast Growth Factor-23 in Innate Immune Responses","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/jbmr.4003","article-title":"IL-1\u03b2 Drives Production of FGF-23 at the Onset of Chronic Kidney Disease in Mice","volume":"35","author":"McKnight","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jbmr.1740","article-title":"Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes","volume":"28","author":"Bacchetta","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MNH.0000000000000232","article-title":"Inflammation regulates fibroblast growth factor 23 production","volume":"25","author":"Francis","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1161\/CIRCULATIONAHA.114.008788","article-title":"Immune Cell and Other Noncardiomyocyte Regulation of Cardiac Hypertrophy and Remodeling","volume":"131","author":"Frieler","year":"2015","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1210\/me.2009-0085","article-title":"Novel Regulators of Fgf23 Expression and Mineralization in Hyp Bone","volume":"23","author":"Liu","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"ref_40","first-page":"E38","article-title":"Pathogenic role of Fgf23 in Hyp mice","volume":"291","author":"Liu","year":"2006","journal-title":"Am. J. Physiol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-30098-1","article-title":"Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II","volume":"8","author":"Pi","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_42","first-page":"829","article-title":"Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure","volume":"3","author":"Wohlfahrt","year":"2015","journal-title":"JACC: Hear. Fail."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Dai, B., David, V., Martin, A., Huang, J., Li, H., Jiao, Y., Gu, W., and Quarles, L.D. (2012). A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044161"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kuga, K., Kusakari, Y., Uesugi, K., Semba, K., Urashima, T., Akaike, T., and Minamisawa, S. (2020). Fibrosis growth factor 23 is a promoting factor for cardiac fibrosis in the presence of transforming growth factor-\u03b21. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0231905"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1096\/fj.15-279943","article-title":"Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by \u03b2-blocker treatment","volume":"30","author":"Fajol","year":"2015","journal-title":"FASEB J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1681\/ASN.2014040325","article-title":"Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate","volume":"26","author":"Xie","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ndt\/gfab254","article-title":"The intersection of mineralocorticoid receptor activation and the FGF23\u2013Klotho cascade: A duopoly that promotes renal and cardiovascular injury","volume":"37","author":"Epstein","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ki.2010.194","article-title":"FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease","volume":"78","author":"Yilmaz","year":"2010","journal-title":"Kidney Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/ndt\/gft523","article-title":"FGF23 protein expression in coronary arteries is associated with impaired kidney function","volume":"29","author":"Pereira","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00424-016-1858-x","article-title":"Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells","volume":"468","author":"Richter","year":"2016","journal-title":"Pfl\u00fcg. Archiv-Eur. J. Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MNH.0000000000000799","article-title":"Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease","volume":"31","author":"Kainz","year":"2022","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.jrn.2008.10.024","article-title":"Salivary Phosphorus and Phosphate Content of Beverages: Implications for the Treatment of Uremic Hyperphosphatemia","volume":"19","author":"Savica","year":"2009","journal-title":"J. Ren. Nutr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/sdi.12956","article-title":"Updates on hemodialysis techniques with a common denominator: The personalization of the dialytic therapy","volume":"34","author":"Monardo","year":"2021","journal-title":"Semin. Dial."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zhao, S.-J., Wang, Z.-X., Chen, L., Wang, F.-X., and Kong, L.-D. (2021). Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Ann. Palliat. Med.","DOI":"10.21037\/apm-21-1943"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MNH.0000000000000514","article-title":"Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease","volume":"28","author":"Babitt","year":"2019","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1210\/jc.2011-1239","article-title":"Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans","volume":"96","author":"Imel","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Flamme, I., Ellinghaus, P., Urrego, D., and Kr\u00fcger, T. (2017). FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186979"},{"key":"ref_59","first-page":"2057","article-title":"Effects of erythropoietin on fibroblast growth factor 23 in mice and humans","volume":"34","author":"Hanudel","year":"2018","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Czaya, B., and Faul, C. (2019). The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174195"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","article-title":"FGF-23 Is a Negative Regulator of Prenatal and Postnatal Erythropoiesis","volume":"289","author":"Coe","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1096\/fj.201700667R","article-title":"Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia","volume":"32","author":"Agoro","year":"2018","journal-title":"FASEB J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/ndt\/gfac162","article-title":"Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD","volume":"37","author":"Biruete","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.kint.2019.07.026","article-title":"Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease","volume":"96","author":"Francis","year":"2019","journal-title":"Kidney Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1038\/s41598-018-25439-z","article-title":"Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease","volume":"8","author":"Nam","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2215\/CJN.03950417","article-title":"Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study","volume":"12","author":"Mehta","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_67","first-page":"e124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.23876\/j.krcp.20.015","article-title":"Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up","volume":"39","author":"Lacquaniti","year":"2020","journal-title":"Kidney Res. Clin. Pr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000451060","article-title":"Distinct in vitro Complement Activation by Various Intravenous Iron Preparations","volume":"45","author":"Hempel","year":"2016","journal-title":"Am. J. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_71","first-page":"1115","article-title":"Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: Path analyses","volume":"34","author":"Fishbane","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1159\/000489964","article-title":"Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients","volume":"47","author":"Maruyama","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Bielesz, B., Reiter, T., Hammerle, F.P., Winnicki, W., Bojic, M., Gleiss, A., Kieweg, H., Ratzinger, F., Sunder-Plassmann, G., and Marculescu, R. (2020). The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082640"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e14434","DOI":"10.14814\/phy2.14434","article-title":"Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)","volume":"8","author":"Noonan","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.kint.2021.03.019","article-title":"Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone","volume":"100","author":"Hanudel","year":"2021","journal-title":"Kidney Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/ki.2010.313","article-title":"Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease","volume":"78","author":"Hasegawa","year":"2010","journal-title":"Kidney Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease\u2013associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J. Clin. Investig."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/4\/609\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:33:53Z","timestamp":1760121233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/4\/609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cells12040609"],"URL":"https:\/\/doi.org\/10.3390\/cells12040609","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]}}}